Last 800.70
Change Today 0.00 / 0.00%
Volume 0.0
As of 10:24 AM 12/18/14 All times are local (Market data is delayed by at least 15 minutes).

protalix biotherapeutics inc (PLX) Snapshot

Open
$794.00
Previous Close
$797.30
Day High
$803.00
Day Low
$794.00
52 Week High
03/6/14 - $1,845
52 Week Low
11/11/14 - $713.00
Market Cap
748.7M
Average Volume 10 Days
99.3K
EPS TTM
--
Shares Outstanding
93.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PROTALIX BIOTHERAPEUTICS INC (PLX)

protalix biotherapeutics inc (PLX) Related Businessweek News

No Related Businessweek News Found

protalix biotherapeutics inc (PLX) Details

Protalix BioTherapeutics, Inc., a biopharmaceutical company, together with its subsidiary, Protalix Ltd., focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system. It offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company’s product pipeline includes PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-112, an orally administered glucocerebrosidase enzyme for the treatment of Gaucher patients utilizing oral delivery of the recombinant glucocerebrosidase enzyme produced and encapsulated within carrot cells; and PRX-106, an oral antiTNF, a plant cell expressed recombinant fusion protein combined of the binding domain of the human TNF receptor and an antibody portion, which is being developed for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, colitis, Crohn’s disease, psoriasis, and other autoimmune and inflammatory disorders. Its product pipeline also comprises PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 under development for the treatment of Cystic Fibrosis, to be administered by inhalation; and PRX-107, a proprietary plant cell recombinant human Alpha1-antitrypsin and others. The company has a collaboration and licensing agreement with Teva Pharmaceutical Industries Ltd. to develop and manufacture two proteins using its ProCellEx protein expression system. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

260 Employees
Last Reported Date: 03/13/14
Founded in 1993

protalix biotherapeutics inc (PLX) Top Compensated Officers

Founder and Executive Vice President of Resea...
Total Annual Compensation: $422.9K
Chief Financial Officer, Vice President, Secr...
Total Annual Compensation: $402.1K
Chief Operating Officer
Total Annual Compensation: $251.7K
Senior Vice President of Product Development
Total Annual Compensation: $361.5K
Compensation as of Fiscal Year 2013.

protalix biotherapeutics inc (PLX) Key Developments

Protalix BioTherapeutics, Inc. Approves Amendment to the Company's Articles of Incorporation

Protalix BioTherapeutics, Inc. announced at its AGM held on November 10, 2014, the shareholders approved an amendment to the company's articles of incorporation.

Protalix Biotherapeutics, Inc. Proposes Amendment to Articles of Incorporation

Protalix BioTherapeutics, Inc. announced that it will propose amendment to articles of incorporation providing that one-third (1/3) of the votes entitled to be cast on any matter by a voting group shall constitute a quorum of that voting group for action on that matter at the Annual Meeting of Shareholders to be held on November 10, 2014.

Protalix BioTherapeutics, Inc., Annual General Meeting, Nov 10, 2014

Protalix BioTherapeutics, Inc., Annual General Meeting, Nov 10, 2014., at 18:30 Israel Standard Time. Location: 2 Snunit Street. Agenda: To elect seven members to the board of directors to serve for the ensuing year or until their respective successors have been duly elected; to approve the compensation of executive officers; to approve the frequency (every one, two or three years) that shareholders of the company will have a non-binding, advisory vote on the compensation of the company's named executive officers; to approve an amendment to articles of incorporation providing that one-third (1/3) of the votes entitled to be cast on any matter by a voting group shall constitute a quorum of that voting group for action on that matter; to adopt amendments to the stock incentive plan; to ratify the appointment of Kesselman & Kesselman as independent registered public accounting firm for the fiscal year ending December 31, 2014; and to transact such other business that is properly presented at the meeting or any adjournment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PLX:IT 800.70 0.00

PLX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PLX.
View Industry Companies
 

Industry Analysis

PLX

Industry Average

Valuation PLX Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTALIX BIOTHERAPEUTICS INC, please visit www.protalix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.